First quarter
Sales of SEK 807 (842) million, an increase of 5% in local currencies and 4% decrease in SEK.
Sales per region, in local currencies, were -1% in EMEA, +11% in Americas and +7% in APAC.
Sales per product group, in local currencies were +9% in Consumables, +11% in Technologies and -1% in Genetics.
Gross margin increase to 59.9% (57.4).
Earnings before depreciation and amortisation (EBITDA) amounted to SEK 251 (257) million, resulting in an EBITDA margin of 31.1% (30.6).
Net income amounted to SEK 101 (100) million, resulting in earnings per share of SEK 0.74 (0.74).
Operating cash flow amounted to SEK 172 (69) million.
Gothenburg, April 23, 2026
VITROLIFE AB (publ)
Bronwyn Brophy O'Connor, CEO
This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 23-04-2026 08:00 CET.